Gilead rescues biopharma’s takeout scene
A few multi-billion-dollar deals got done in the third quarter, but 2020’s acquisition scene still looks anaemic.
J&J snags novel autoimmune project, and Momenta
The $6.5bn price – biopharma’s biggest buyout of the year so far – shows how competitive the anti-FcRn space has become.
Argenx sets a high bar with a novel drug class
A new mechanism for certain autoimmune conditions takes a big step forward with impressive pivotal data on Argenx’s efgartigimod.
Upcoming events – Wave takes on Huntington's and Argenx goes subcutaneous
After a delay Wave will finally see data for its Huntington's disease projects while Argenx's subcutaneous efgartigimod needs to keep the competition at bay.
UCB goes to Ra for a complementary approach
The $2bn takeout of Ra Pharmaceuticals provides solace for investors bemoaning the biotech market’s poor performance.
Abbvie manoeuvres to defend Humira to the last
Abbvie's latest move to shore up Humira sales against a biosimilar onslaught involves politically sensitive price hikes.